Neoplasms

Symptoms and General Pathology

All Conditions

Rare Diseases

Neoplasm Metastasis

Neuroendocrine Tumors

Neoplastic Processes

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Hematinics

Doxorubicin

Liposomal doxorubicin

Chlorotrianisene

Liver Extracts

Ethiodized Oil

Lobar or segmental bland embolization (BE) with microspheres (50-500 microns) to 2-5 heartbeat stasis.

Lobar or segmental lipiodol conventional transarterial chemoembolization (TACE). Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.

Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU monthly until entire tumor burden is treated.

Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis

Bland Embolization

Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.

Transarterial chemoembolization

CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.

Drug Eluting Beads Embolization

Michael C Soulen, MD, FSIR

The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

Hepatic progression-free interval (H-PFS)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver	NCT02724540	Neuroendocrine ... Liver Metastase...	Bland Embolizat... Transarterial c... Drug Eluting Be...	18 Years -	Abramson Cancer Center at Penn Medicine
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver	NCT02724540	Neuroendocrine ... Liver Metastase...	Bland Embolizat... Transarterial c... Drug Eluting Be...	18 Years -	Abramson Cancer Center at Penn Medicine

Spots Global Cancer Trial Database for drug eluting beads embolization